You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameParoxetine
Accession NumberDB00715
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionParoxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.
Structure
Thumb
Synonyms
(-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
Paroxetina
Paroxetine
Paroxetinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act ParoxetineTablet20 mgOralActavis Pharma Company2005-03-14Not applicableCanada
Act ParoxetineTablet30 mgOralActavis Pharma Company2005-03-14Not applicableCanada
Act ParoxetineTablet10 mgOralActavis Pharma Company2005-03-14Not applicableCanada
Auro-paroxetineTablet30 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-paroxetineTablet10 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-paroxetineTablet20 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Bio-paroxetineTablet10 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-paroxetineTablet20 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-paroxetineTablet30 mgOralBiomed PharmaNot applicableNot applicableCanada
BrisdelleCapsule7.5 mg/1OralNOVEN THERAPEUTICS, LLC2013-06-28Not applicableUs
Dom-paroxetineTablet10 mgOralDominion Pharmacal2004-02-06Not applicableCanada
Dom-paroxetineTablet40 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-paroxetineTablet20 mgOralDominion Pharmacal2004-02-06Not applicableCanada
Dom-paroxetineTablet30 mgOralDominion Pharmacal2004-02-06Not applicableCanada
Ipg-paroxetineTablet30 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-paroxetineTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-paroxetineTablet20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-paroxetineTablet10 mgOralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-paroxetineTablet20 mgOralJamp Pharma Corporation2011-10-24Not applicableCanada
Jamp-paroxetineTablet30 mgOralJamp Pharma Corporation2011-10-06Not applicableCanada
Mar-paroxetineTablet20 mgOralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mar-paroxetineTablet10 mgOralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mar-paroxetineTablet30 mgOralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mint-paroxetineTablet20 mgOralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-paroxetineTablet30 mgOralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-paroxetineTablet10 mgOralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mylan-paroxetineTablet10 mgOralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Mylan-paroxetineTablet20 mgOralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Mylan-paroxetineTablet30 mgOralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Ntp-paroxetineTablet20 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-paroxetineTablet30 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-paroxetineTablet10 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-paroxetineTablet20 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-paroxetineTablet30 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-paroxetineTablet10 mgOralNu Pharm IncNot applicableNot applicableCanada
ParoxetineTablet10 mgOralMeliapharm Inc2004-04-062014-06-25Canada
ParoxetineTablet20 mgOralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
ParoxetineTablet30 mgOralSanis Health Inc2009-10-22Not applicableCanada
ParoxetineTablet20 mgOralMeliapharm Inc2004-04-062014-06-25Canada
ParoxetineTablet10 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
ParoxetineTablet30 mgOralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
ParoxetineTablet10 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
ParoxetineTablet10 mgOralSanis Health Inc2009-10-22Not applicableCanada
ParoxetineTablet30 mgOralMeliapharm Inc2004-04-062014-06-25Canada
ParoxetineTablet20 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
ParoxetineTablet20 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
ParoxetineTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
ParoxetineTablet20 mgOralSanis Health Inc2009-10-22Not applicableCanada
ParoxetineTablet30 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
ParoxetineTablet30 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
Paroxetine HydrochlorideTablet, film coated, extended release25 mg/1Oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release12.5 mg/1Oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release12.5 mg/1OralApotex Corp2010-09-13Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release37.5 mg/1Oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release25 mg/1OralApotex Corp2010-09-13Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release37.5 mg/1OralApotex Corp2010-09-132016-10-17Us
Paroxetine-10Tablet10 mgOralPro Doc Limitee2004-03-19Not applicableCanada
Paroxetine-20Tablet20 mgOralPro Doc Limitee2004-03-19Not applicableCanada
Paroxetine-30Tablet30 mgOralPro Doc Limitee2004-03-19Not applicableCanada
PaxilTablet, film coated40 mg/1OralApotex Corp2011-01-01Not applicableUs
PaxilTablet, film coated10 mg/1OralApotex Corp2011-01-01Not applicableUs
PaxilTablet, film coated30 mg/1OralPhysicians Total Care, Inc.1996-07-10Not applicableUs
PaxilTablet, film coated20 mg/1OralApotex Corp2011-01-01Not applicableUs
PaxilTablet, film coated30 mg/1OralApotex Corp2011-01-01Not applicableUs
PaxilSuspension10 mg/5mLOralApotex Corp2011-01-01Not applicableUs
PaxilTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2006-09-18Not applicableUs
Paxil CRTablet, film coated, extended release12.5 mg/1OralSTAT Rx USA LLC2002-04-09Not applicableUs
Paxil CRTablet, film coated, extended release37.5 mg/1OralApotex Corp2011-01-01Not applicableUs
Paxil CRTablet, extended release25 mgOralGlaxosmithkline Inc2004-01-05Not applicableCanada
Paxil CRTablet, film coated, extended release12.5 mg/1OralRebel Distributors Corp2002-04-09Not applicableUs
Paxil CRTablet, film coated, extended release12.5 mg/1OralApotex Corp2011-01-01Not applicableUs
Paxil CRTablet, film coated, extended release25 mg/1OralRebel Distributors Corp2002-04-09Not applicableUs
Paxil CRTablet, extended release37.5 mgOralGlaxosmithkline IncNot applicableNot applicableCanada
Paxil CRTablet, extended release12.5 mgOralGlaxosmithkline Inc2004-01-05Not applicableCanada
Paxil CRTablet, film coated, extended release25 mg/1OralApotex Corp2011-01-01Not applicableUs
Paxil Tab 10mgTablet10 mgOralGlaxosmithkline Inc1997-01-31Not applicableCanada
Paxil Tab 20mgTablet20 mgOralGlaxosmithkline Inc1993-12-31Not applicableCanada
Paxil Tab 30mgTablet30 mgOralGlaxosmithkline Inc1993-12-31Not applicableCanada
Paxilcr CRTablet, film coated, extended release37.5 mg/1OralPhysicians Total Care, Inc.2005-07-21Not applicableUs
Paxilcr CRTablet, film coated, extended release25 mg/1OralPhysicians Total Care, Inc.2003-05-16Not applicableUs
Paxilcr CRTablet, film coated, extended release12.5 mg/1OralPhysicians Total Care, Inc.2005-07-06Not applicableUs
PexevaTablet, film coated40 mg/1OralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
PexevaTablet, film coated10 mg/1OralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
PexevaTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-02-23Not applicableUs
PexevaTablet, film coated20 mg/1OralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
PexevaTablet, film coated30 mg/1OralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
PMS-paroxetineTablet10 mgOralPharmascience Inc2003-10-29Not applicableCanada
PMS-paroxetineTablet40 mgOralPharmascience Inc2007-05-03Not applicableCanada
PMS-paroxetineTablet20 mgOralPharmascience Inc2003-10-29Not applicableCanada
PMS-paroxetineTablet30 mgOralPharmascience Inc2003-10-29Not applicableCanada
Priva-paroxetineTablet10 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-paroxetineTablet20 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-paroxetineTablet30 mgOralPharmapar IncNot applicableNot applicableCanada
Q-paroxetineTablet10 mgOralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Q-paroxetineTablet20 mgOralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Q-paroxetineTablet30 mgOralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Ratio-paroxetineTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Ratio-paroxetineTablet20 mgOralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Ratio-paroxetineTablet30 mgOralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Riva-paroxetineTablet20 mgOralLaboratoire Riva Inc2004-02-16Not applicableCanada
Riva-paroxetineTablet30 mgOralLaboratoire Riva Inc2004-02-16Not applicableCanada
Riva-paroxetineTablet10 mgOralLaboratoire Riva Inc2004-02-16Not applicableCanada
Sandoz ParoxetineTablet20 mgOralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz ParoxetineTablet30 mgOralSandoz Canada Incorporated2004-09-212012-02-20Canada
Sandoz ParoxetineTablet30 mgOralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz ParoxetineTablet10 mgOralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz ParoxetineTablet20 mgOralSandoz Canada Incorporated2004-09-212012-02-20Canada
Sandoz Paroxetine TabletsTablet30 mgOralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Paroxetine TabletsTablet10 mgOralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Paroxetine TabletsTablet20 mgOralSandoz Canada Incorporated2014-10-31Not applicableCanada
Teva-paroxetineTablet10 mgOralTeva Canada Limited2004-01-16Not applicableCanada
Teva-paroxetineTablet20 mgOralTeva Canada Limited2004-01-16Not applicableCanada
Teva-paroxetineTablet30 mgOralTeva Canada Limited2004-01-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-paroxetineTablet10 mgOralApotex Inc2003-10-24Not applicableCanada
Apo-paroxetineTablet20 mgOralApotex Inc2003-10-24Not applicableCanada
Apo-paroxetineTablet30 mgOralApotex Inc2003-10-24Not applicableCanada
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2016-09-19Not applicableUs
ParoxetineTablet, film coated40 mg/1OralMajor Pharmaceuticals2010-06-07Not applicableUs
ParoxetineTablet, film coated20 mg/1OralPreferred Pharmaceuticals, Inc.2012-12-20Not applicableUs
ParoxetineTablet, film coated20 mg/1OralCardinal Health2004-02-14Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2015-03-03Not applicableUs
ParoxetineTablet, film coated20 mg/1OralContract Pharmacy Services Pa2010-08-11Not applicableUs
ParoxetineTablet, film coated10 mg/1OralAurolife Pharma LLC2009-12-03Not applicableUs
ParoxetineTablet, film coated30 mg/1OralLucid Pharma Llc2007-07-25Not applicableUs
ParoxetineTablet, film coated40 mg/1OralSolco Healthcare US, LLC2014-11-01Not applicableUs
ParoxetineTablet, film coated20 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
ParoxetineTablet, film coated20 mg/1OralH.J. Harkins Company, Inc.2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralAurobindo Pharma Limited2007-07-25Not applicableUs
ParoxetineTablet, film coated20 mg/1OralAv Pak2016-03-11Not applicableUs
ParoxetineTablet10 mg/1OralInternational Laboratories, Inc.2007-12-11Not applicableUs
ParoxetineTablet, film coated40 mg/1OralA S Medication Solutions2009-12-03Not applicableUs
ParoxetineTablet, film coated20 mg/1OralMajor Pharmaceuticals2003-09-08Not applicableUs
ParoxetineTablet, film coated40 mg/1OralA S Medication Solutions2009-12-03Not applicableUs
ParoxetineTablet, film coated10 mg/1OralTeva Pharmaceuticals USA Inc2005-11-07Not applicableUs
ParoxetineTablet, film coated10 mg/1OralCardinal Health2011-05-19Not applicableUs
ParoxetineTablet, film coated20 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
ParoxetineTablet, film coated30 mg/1OralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
ParoxetineTablet, film coated10 mg/1OralTYA Pharmaceuticals2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-10-31Not applicableUs
ParoxetineTablet, film coated20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-12-03Not applicableUs
ParoxetineTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2007-04-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralSt. Mary's Medical Park Pharmacy2015-06-11Not applicableUs
ParoxetineTablet, film coated40 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
ParoxetineTablet, film coated20 mg/1OralPreferred Pharmaceuticals, Inc2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralSTAT Rx USA LLC2007-07-25Not applicableUs
ParoxetineTablet, film coated30 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated20 mg/1OralMylan Institutional Inc.2005-12-26Not applicableUs
ParoxetineTablet, film coated20 mg/1OralGreenstone LLC2007-07-252016-10-31Us
ParoxetineTablet30 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated10 mg/1OralAmerican Health Packaging2011-05-19Not applicableUs
ParoxetineTablet, film coated20 mg/1OralRebel Distributors Corp2007-04-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralClinical Solutions Wholesale2009-12-03Not applicableUs
ParoxetineTablet, film coated10 mg/1OralTrupharma, Llc2016-09-30Not applicableUs
ParoxetineTablet, film coated10 mg/1OralRebel Distributors Corp2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralCardinal Health2007-04-132016-02-25Us
ParoxetineTablet, film coated10 mg/1Oralbryant ranch prepack2003-09-08Not applicableUs
ParoxetineTablet, film coated10 mg/1OralApotex Corp.2003-09-08Not applicableUs
ParoxetineTablet, film coated40 mg/1OralCadila Healthcare Limited2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-06-11Not applicableUs
ParoxetineTablet, film coated10 mg/1OralSolco Healthcare US, LLC2014-11-01Not applicableUs
ParoxetineTablet40 mg/1OralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
ParoxetineTablet, film coated20 mg/1OralUnit Dose Services2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralProficient Rx LP2009-12-03Not applicableUs
ParoxetineTablet, film coated20 mg/1OralMc Kesson Contract Packaging2011-09-16Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-12-05Not applicableUs
ParoxetineTablet, film coated20 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-07-25Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-07-23Not applicableUs
ParoxetineTablet, film coated10 mg/1OralMajor Pharmaceuticals2010-06-07Not applicableUs
ParoxetineTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2004-04-07Not applicableUs
ParoxetineTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2008-03-24Not applicableUs
ParoxetineTablet, film coated40 mg/1OralA S Medication Solutions2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2016-10-07Not applicableUs
ParoxetineTablet, film coated20 mg/1OralBlenheim Pharmacal, Inc.2014-02-06Not applicableUs
ParoxetineTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2007-07-25Not applicableUs
ParoxetineTablet, film coated10 mg/1OralCardinal Health2004-02-14Not applicableUs
ParoxetineTablet, film coated30 mg/1OralContract Pharmacy Services Pa2010-08-11Not applicableUs
ParoxetineTablet, film coated20 mg/1OralAurolife Pharma LLC2009-12-03Not applicableUs
ParoxetineTablet, film coated40 mg/1OralLucid Pharma Llc2007-07-25Not applicableUs
ParoxetineTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-04-13Not applicableUs
ParoxetineTablet, film coated30 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
ParoxetineTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated20 mg/1OralAurobindo Pharma Limited2007-07-25Not applicableUs
ParoxetineTablet, film coated30 mg/1OralAv Pak2016-03-11Not applicableUs
ParoxetineTablet, film coated10 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
ParoxetineTablet40 mg/1OralREMEDYREPACK INC.2011-01-032016-10-26Us
ParoxetineTablet, film coated30 mg/1OralMajor Pharmaceuticals2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-11-01Not applicableUs
ParoxetineTablet, film coated20 mg/1OralTeva Pharmaceuticals USA Inc2005-10-03Not applicableUs
ParoxetineTablet, film coated30 mg/1OralDIRECT RX2015-01-01Not applicableUs
ParoxetineTablet, film coated40 mg/1OralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
ParoxetineTablet, film coated10 mg/1OralCadila Healthcare Limited2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-03-11Not applicableUs
ParoxetineTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2013-02-04Not applicableUs
ParoxetineTablet10 mg/1OralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
ParoxetineTablet, film coated20 mg/1OralProficient Rx LP2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralCardinal Health2003-09-08Not applicableUs
ParoxetineTablet, film coated10 mg/1Oralbryant ranch prepack2003-09-08Not applicableUs
ParoxetineTablet, film coated10 mg/1OralSTAT Rx USA LLC2007-07-25Not applicableUs
ParoxetineTablet, film coated40 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
ParoxetineTablet, film coated30 mg/1OralGreenstone LLC2007-07-252016-08-31Us
ParoxetineTablet30 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated20 mg/1OralAmerican Health Packaging2011-05-19Not applicableUs
ParoxetineTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2015-05-05Not applicableUs
ParoxetineTablet, film coated20 mg/1OralTrupharma, Llc2016-09-30Not applicableUs
ParoxetineTablet, film coated20 mg/1OralTYA Pharmaceuticals2007-04-13Not applicableUs
ParoxetineTablet, film coated30 mg/1OralRebel Distributors Corp2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2004-08-17Not applicableUs
ParoxetineTablet, film coated40 mg/1OralApotex Corp.2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralMed Vantx, Inc.2005-10-03Not applicableUs
ParoxetineTablet, film coated30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
ParoxetineTablet, film coated10 mg/1OralLucid Pharma Llc2007-07-25Not applicableUs
ParoxetineTablet, film coated20 mg/1OralSolco Healthcare US, LLC2014-11-01Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-06-04Not applicableUs
ParoxetineTablet, film coated10 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-04-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralDIRECT RX2016-02-29Not applicableUs
ParoxetineTablet30 mg/1OralInternational Laboratories, Inc.2007-12-11Not applicableUs
ParoxetineTablet, film coated20 mg/1OralA S Medication Solutions2009-12-03Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2016-08-31Not applicableUs
ParoxetineTablet, film coated20 mg/1OralMajor Pharmaceuticals2010-06-07Not applicableUs
ParoxetineTablet, film coated30 mg/1OralAurobindo Pharma Limited2007-07-25Not applicableUs
ParoxetineTablet, film coated40 mg/1OralAv Pak2016-03-11Not applicableUs
ParoxetineTablet, film coated20 mg/1OralClinical Solutions Wholesale2009-12-03Not applicableUs
ParoxetineTablet, film coated40 mg/1OralA S Medication Solutions2007-04-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralBlenheim Pharmacal, Inc.2014-02-06Not applicableUs
ParoxetineTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
ParoxetineTablet, film coated10 mg/1OralCardinal Health2010-06-07Not applicableUs
ParoxetineTablet, film coated10 mg/1OralDIRECT RX2014-01-01Not applicableUs
ParoxetineTablet, film coated40 mg/1OralContract Pharmacy Services Pa2010-08-11Not applicableUs
ParoxetineTablet, film coated30 mg/1OralAurolife Pharma LLC2009-12-03Not applicableUs
ParoxetineTablet, film coated10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-11-08Not applicableUs
ParoxetineTablet, film coated40 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
ParoxetineTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet20 mg/1OralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
ParoxetineTablet, film coated10 mg/1OralProficient Rx LP2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
ParoxetineTablet, film coated30 mg/1OralREMEDYREPACK INC.2010-01-27Not applicableUs
ParoxetineTablet, film coated40 mg/1OralMajor Pharmaceuticals2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2016-05-24Not applicableUs
ParoxetineTablet, film coated30 mg/1OralTeva Pharmaceuticals USA Inc2005-11-02Not applicableUs
ParoxetineTablet, film coated10 mg/1OralA S Medication Solutions2009-12-03Not applicableUs
ParoxetineTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2009-02-18Not applicableUs
ParoxetineTablet, film coated20 mg/1OralApotex Corp.2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralCadila Healthcare Limited2007-04-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralREMEDYREPACK INC.2014-04-10Not applicableUs
ParoxetineTablet, film coated40 mg/1OralAphena Pharma Solutions Tennessee, Llc2008-03-24Not applicableUs
ParoxetineTablet, film coated10 mg/1OralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
ParoxetineTablet, film coated40 mg/1Oralbryant ranch prepack2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralAidarex Pharmaceuticals LLC2007-04-13Not applicableUs
ParoxetineTablet, film coated30 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralGreenstone LLC2007-07-252016-06-30Us
ParoxetineTablet40 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated30 mg/1OralAmerican Health Packaging2011-05-19Not applicableUs
ParoxetineTablet, film coated20 mg/1OralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2015-06-02Not applicableUs
ParoxetineTablet, film coated30 mg/1OralTrupharma, Llc2016-09-30Not applicableUs
ParoxetineTablet, film coated10 mg/1OralTYA Pharmaceuticals2007-04-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralRebel Distributors Corp2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-10-03Not applicableUs
ParoxetineTablet, film coated10 mg/1OralContract Pharmacy Services Pa2010-08-11Not applicableUs
ParoxetineTablet, film coated40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
ParoxetineTablet, film coated20 mg/1OralLucid Pharma Llc2007-07-25Not applicableUs
ParoxetineTablet, film coated30 mg/1OralSolco Healthcare US, LLC2014-11-01Not applicableUs
ParoxetineTablet, film coated10 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
ParoxetineTablet, film coated10 mg/1OralH.J. Harkins Company, Inc.2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralAv Pak2016-03-11Not applicableUs
ParoxetineTablet20 mg/1OralInternational Laboratories, Inc.2007-12-11Not applicableUs
ParoxetineTablet, film coated20 mg/1OralA S Medication Solutions2003-09-08Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-08-31Not applicableUs
ParoxetineTablet, film coated30 mg/1OralMajor Pharmaceuticals2010-06-07Not applicableUs
ParoxetineTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2012-12-20Not applicableUs
ParoxetineTablet, film coated20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralGreenstone LLC2007-07-252016-08-31Us
ParoxetineTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated40 mg/1OralAurobindo Pharma Limited2007-07-25Not applicableUs
ParoxetineTablet, film coated40 mg/1OralPd Rx Pharmaceuticals, Inc.2008-03-24Not applicableUs
ParoxetineTablet, film coated30 mg/1OralClinical Solutions Wholesale2009-12-03Not applicableUs
ParoxetineTablet, film coated10 mg/1OralA S Medication Solutions2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralApotheca Inc.2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralCardinal Health2010-06-07Not applicableUs
ParoxetineTablet, film coated20 mg/1Oralbryant ranch prepack2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc2007-04-13Not applicableUs
ParoxetineTablet, film coated40 mg/1OralAurolife Pharma LLC2009-12-03Not applicableUs
ParoxetineTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-04-14Not applicableUs
ParoxetineTablet, film coated20 mg/1OralAphena Pharma Solutions Tennessee, Llc2008-03-24Not applicableUs
ParoxetineTablet30 mg/1OralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
ParoxetineTablet, film coated40 mg/1OralProficient Rx LP2007-04-13Not applicableUs
ParoxetineTablet, film coated30 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2010-01-28Not applicableUs
ParoxetineTablet, film coated20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-11-01Not applicableUs
ParoxetineTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-06-16Not applicableUs
ParoxetineTablet, film coated40 mg/1OralTeva Pharmaceuticals USA Inc2005-11-02Not applicableUs
ParoxetineTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2008-10-15Not applicableUs
ParoxetineTablet, film coated30 mg/1OralApotex Corp.2003-09-08Not applicableUs
ParoxetineTablet, film coated30 mg/1OralCadila Healthcare Limited2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralTYA Pharmaceuticals2003-09-08Not applicableUs
ParoxetineTablet, film coated20 mg/1OralAidarex Pharmaceuticals LLC2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralCardinal Health2011-01-14Not applicableUs
ParoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralSt. Mary's Medical Park Pharmacy2015-06-11Not applicableUs
ParoxetineTablet40 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
ParoxetineTablet, film coated40 mg/1OralAmerican Health Packaging2011-05-19Not applicableUs
ParoxetineTablet, film coated30 mg/1OralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
ParoxetineTablet, film coated10 mg/1OralMajor Pharmaceuticals2003-09-08Not applicableUs
ParoxetineTablet, film coated40 mg/1OralTrupharma, Llc2016-09-30Not applicableUs
ParoxetineTablet, film coated20 mg/1OralCardinal Health2011-05-19Not applicableUs
ParoxetineTablet10 mg/1OralREMEDYREPACK INC.2011-04-18Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release12.5 mg/1OralMylan Pharmaceuticals Inc.2008-05-14Not applicableUs
Paroxetine HydrochlorideTablet20 mg/1OralREMEDYREPACK INC.2011-03-29Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release37.5 mg/1OralKremers Urban Pharmaceuticals Inc.2014-10-31Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release25 mg/1OralAv Kare, Inc.2016-11-02Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release25 mg/1OralPhysicians Total Care, Inc.2008-05-23Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release25 mg/1OralMylan Pharmaceuticals Inc.2008-05-14Not applicableUs
Paroxetine HydrochlorideTablet20 mg/1OralREMEDYREPACK INC.2011-07-11Not applicableUs
Paroxetine HydrochlorideTablet20 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release37.5 mg/1OralAv Kare, Inc.2016-11-02Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release12.5 mg/1OralKremers Urban Pharmaceuticals Inc.2014-10-31Not applicableUs
Paroxetine HydrochlorideTablet20 mg/1OralREMEDYREPACK INC.2011-07-21Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release37.5 mg/1OralMylan Pharmaceuticals Inc.2011-05-05Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release12.5 mg/1OralPhysicians Total Care, Inc.2010-10-25Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release25 mg/1OralKremers Urban Pharmaceuticals Inc.2014-10-31Not applicableUs
Paroxetine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2011-11-03Not applicableUs
Paroxetine HydrochlorideTablet, film coated, extended release12.5 mg/1OralAv Kare, Inc.2016-11-02Not applicableUs
Paroxetine Hydrochloride AnhydrousTablet, film coated20 mg/1OralDIRECT RX2014-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AropaxNot Available
PAXILCRNot Available
SereupinNot Available
SeroxatNot Available
Seroxat CRNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Paroxetine hydrochloride
Thumb
  • InChI Key: GELRVIPPMNMYGS-RVXRQPKJSA-N
  • Monoisotopic Mass: 365.119399455
  • Average Mass: 365.826
DBSALT000132
Paroxetine hydrochloride hemihydrate
ThumbNot applicableDBSALT001742
Paroxetine mesylate
Thumb
  • InChI Key: SHIJTGJXUHTGGZ-RVXRQPKJSA-N
  • Monoisotopic Mass: 425.1308364
  • Average Mass: 425.471
DBSALT000133
Categories
UNII41VRH5220H
CAS number61869-08-7
WeightAverage: 329.3654
Monoisotopic: 329.142721716
Chemical FormulaC19H20FNO3
InChI KeyAHOUBRCZNHFOSL-YOEHRIQHSA-N
InChI
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
IUPAC Name
(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
SMILES
FC1=CC=C(C=C1)[C@@H]1CCNC[[email protected]]1COC1=CC2=C(OCO2)C=C1
Pharmacology
IndicationLabeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.
Structured Indications
PharmacodynamicsParoxetine, an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) type, has no active metabolites and has the highest specificity for serotonin receptors of all the SSRIs. It is used to treat depression resistant to other antidepressants, depression complicated by anxiety, panic disorder, social and general anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder, premature ejaculation, and hot flashes of menopause in women with breast cancer. In human platelets, paroxetine blocks the uptake of serotonin. It has weak effects on norepinephrine and dopamine neuronal reuptake. In vitro radioligand binding studies indicate that paroxetine has little affinity for muscarinic alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine (H1)-receptors.
Mechanism of actionParoxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Sodium-dependent noradrenaline transporterProteinunknown
inhibitor
HumanP23975 details
5-hydroxytryptamine receptor 2AProteinunknown
other/unknown
HumanP28223 details
Muscarinic acetylcholine receptor M1Proteinno
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinno
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinno
antagonist
HumanP08912 details
Related Articles
AbsorptionParoxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable.
Volume of distribution

3.1-28 L/kg observed in animal studies. Paroxetine distributes throughout the body, including the central nervous system, with only 1% remaining in the plasma.

Protein binding~ 95% bound to plasma proteins.
Metabolism

Paroxetine is extensively metabolized after oral administration, likely in the liver. The main metabolites are polar and conjugated products of oxidation and methylation, which are readily eliminated by the body. The predominant metabolites are glucuronic acid and sulfate conjugates. Paroxetine metabolites do not possess significant pharmacologic activity (less than 2% that of parent compound). Paroxetine is metabolized by cytochrome P450 (CYP) 2D6. Enzyme saturation appears to account for the nonlinear pharmacokinetics observed with increasing dose and duration of therapy.

Route of eliminationApproximately 64% of a 30 mg oral solution of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites. Approximately 36% of the dose was excreted in the feces (via bile), mostly as metabolites and less than 1% as parent compound.
Half life21-24 hours
ClearanceNot Available
ToxicityLD50=500mg/kg (orally in mice). Symptoms of overdose include: coma, dizziness, drowsiness, facial flushing, nausea, sweating, tremor, vomiting. Side effects include: nervous system effects such as asthenia, somnolence, dizziness, insomnia, tremor, and nervousness; GI effects such as nausea, decreased appetite, constipation, diarrhea, and dry mouth; impotence, ejaculatory dysfunction (principally ejaculatory delay), and other male genital disorders; female genital disorders (principally anorgasmia or difficulty reaching climax/orgasm); and sweating. Discontinuation syndrome may occur with abrupt withdrawal. Symptoms of discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory changes, and hyperactivity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableC AlleleImproved response to antidepressant medication17913323
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableC AlleleC Allele potentially associated with discontinuation syndrome in patients treated for anxiety or depression.20075642
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Paroxetine.Investigational
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Paroxetine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Paroxetine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Paroxetine.Experimental
AbirateroneThe serum concentration of Paroxetine can be increased when it is combined with Abiraterone.Approved
AcarboseParoxetine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Paroxetine.Approved
AcenocoumarolParoxetine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Paroxetine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Paroxetine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Paroxetine.Approved
Acetylsalicylic acidParoxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Paroxetine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Paroxetine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Paroxetine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Paroxetine.Approved
AlbiglutideParoxetine may increase the hypoglycemic activities of Albiglutide.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Paroxetine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Paroxetine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Paroxetine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Paroxetine.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Paroxetine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Paroxetine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Paroxetine.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Paroxetine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paroxetine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Paroxetine.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Paroxetine.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Paroxetine.Approved, Withdrawn
AmiodaroneParoxetine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Paroxetine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Paroxetine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Paroxetine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Paroxetine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Paroxetine.Approved
AnagrelideParoxetine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Paroxetine.Approved
Aop200704The serum concentration of Aop200704 can be increased when it is combined with Paroxetine.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Paroxetine.Approved
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Paroxetine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Paroxetine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Paroxetine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Paroxetine.Approved
Arsenic trioxideParoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherParoxetine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Paroxetine.Approved
AsenapineParoxetine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Paroxetine.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Paroxetine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Paroxetine.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Paroxetine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Azaperone.Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Paroxetine.Approved
AzithromycinParoxetine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Paroxetine.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Paroxetine.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine.Illicit
BedaquilineParoxetine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololThe serum concentration of Befunolol can be increased when it is combined with Paroxetine.Experimental
BendroflumethiazideParoxetine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Paroxetine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Paroxetine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Paroxetine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Paroxetine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Paroxetine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Paroxetine.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Paroxetine.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Paroxetine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Paroxetine.Approved
BezitramideBezitramide may increase the serotonergic activities of Paroxetine.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Paroxetine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Paroxetine.Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Paroxetine.Approved
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Paroxetine.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Paroxetine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Paroxetine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paroxetine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Paroxetine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Paroxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Paroxetine.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Paroxetine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Paroxetine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Paroxetine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Paroxetine.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Paroxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Paroxetine.Approved
BuspironeBuspirone may increase the serotonergic activities of Paroxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Paroxetine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Paroxetine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Paroxetine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Paroxetine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Paroxetine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Paroxetine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paroxetine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Paroxetine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Paroxetine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Paroxetine.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Paroxetine.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Paroxetine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Paroxetine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Paroxetine.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Paroxetine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Paroxetine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Paroxetine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Paroxetine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Paroxetine.Approved, Investigational
CelecoxibParoxetine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Paroxetine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Paroxetine.Approved, Vet Approved
CeritinibParoxetine may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Paroxetine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Paroxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Paroxetine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Paroxetine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Paroxetine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paroxetine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Paroxetine.Approved, Vet Approved
ChlorothiazideParoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Paroxetine.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Paroxetine.Approved, Vet Approved
ChlorpropamideParoxetine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneParoxetine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Paroxetine.Approved
CholecalciferolThe metabolism of Paroxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe metabolism of Cilostazol can be decreased when combined with Paroxetine.Approved
CimetidineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Paroxetine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Paroxetine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Paroxetine.Approved
CiprofloxacinParoxetine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideParoxetine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Paroxetine.Approved
CitalopramParoxetine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinParoxetine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Paroxetine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Paroxetine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Paroxetine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Paroxetine.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Paroxetine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Paroxetine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Paroxetine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Paroxetine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Paroxetine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paroxetine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Paroxetine.Approved, Illicit
ClotrimazoleThe metabolism of Paroxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Paroxetine.Approved
CobicistatThe serum concentration of Paroxetine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Paroxetine.Approved
CocaineThe metabolism of Paroxetine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Paroxetine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Paroxetine.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Paroxetine.Approved
CrizotinibParoxetine may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Paroxetine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclobenzaprine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Paroxetine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paroxetine.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Paroxetine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Paroxetine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Paroxetine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Paroxetine.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Paroxetine.Approved, Investigational
DarunavirThe serum concentration of Paroxetine can be decreased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Paroxetine.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Paroxetine.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Paroxetine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Paroxetine.Approved
DelavirdineThe metabolism of Paroxetine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Paroxetine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Paroxetine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Paroxetine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Paroxetine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paroxetine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Paroxetine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Paroxetine.Approved, Illicit
DextromethorphanParoxetine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Paroxetine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Paroxetine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Paroxetine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Paroxetine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Paroxetine.Approved, Vet Approved
DicoumarolParoxetine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Paroxetine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Paroxetine.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Paroxetine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Paroxetine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Paroxetine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paroxetine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Paroxetine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Paroxetine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Paroxetine.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Paroxetine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Paroxetine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Paroxetine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Paroxetine.Approved
DisopyramideParoxetine may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Paroxetine.Approved, Investigational
DofetilideParoxetine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Paroxetine.Approved
DomperidoneParoxetine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Paroxetine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Paroxetine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Paroxetine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Paroxetine.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Paroxetine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Paroxetine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Paroxetine.Approved, Investigational
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Paroxetine.Investigational
DronedaroneParoxetine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolParoxetine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Paroxetine.Experimental, Illicit
DulaglutideParoxetine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineDuloxetine may increase the serotonergic activities of Paroxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Paroxetine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Paroxetine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Paroxetine.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Paroxetine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Paroxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Paroxetine.Approved
EmpagliflozinParoxetine may increase the hypoglycemic activities of Empagliflozin.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Paroxetine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Paroxetine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Paroxetine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Paroxetine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paroxetine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Paroxetine.Approved, Investigational
ErythromycinParoxetine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramParoxetine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Esmirtazapine.Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Paroxetine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paroxetine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Paroxetine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Paroxetine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Paroxetine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paroxetine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Paroxetine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Paroxetine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.Approved
Ethyl biscoumacetateParoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Paroxetine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Paroxetine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Paroxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Paroxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Paroxetine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Paroxetine.Approved
EtodolacParoxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.Approved
EtoperidoneParoxetine may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Paroxetine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Paroxetine.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Paroxetine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Paroxetine.Approved
ExenatideParoxetine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Paroxetine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Paroxetine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineParoxetine may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Paroxetine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Paroxetine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Paroxetine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Paroxetine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Paroxetine.Approved, Illicit
FluindioneParoxetine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Paroxetine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Paroxetine.Approved, Illicit
FluoxetineParoxetine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolParoxetine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Paroxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Paroxetine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Paroxetine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Paroxetine.Approved
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Paroxetine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Paroxetine.Approved, Investigational
FosamprenavirThe serum concentration of Paroxetine can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of the active metabolites of Fosaprepitant can be reduced when Fosaprepitant is used in combination with Paroxetine resulting in a loss in efficacy.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Paroxetine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Paroxetine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Paroxetine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Paroxetine.Approved
Gadobenic acidParoxetine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Paroxetine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Paroxetine.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Paroxetine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Paroxetine.Approved
GemifloxacinParoxetine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Paroxetine.Investigational
GliclazideParoxetine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideParoxetine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideParoxetine may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Paroxetine.Approved, Illicit
GlyburideParoxetine may increase the hypoglycemic activities of Glyburide.Approved
GoserelinParoxetine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Paroxetine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Paroxetine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Paroxetine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Paroxetine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Paroxetine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Paroxetine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Paroxetine.Approved, Vet Approved
HeroinHeroin may increase the serotonergic activities of Paroxetine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Paroxetine.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Paroxetine.Approved
HydrochlorothiazideParoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Paroxetine.Approved, Vet Approved
HydroflumethiazideParoxetine may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Paroxetine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Paroxetine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Paroxetine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Paroxetine.Approved
IbutilideParoxetine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Paroxetine.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Paroxetine.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Paroxetine.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Paroxetine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Paroxetine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Paroxetine.Approved
IndalpineParoxetine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideParoxetine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Paroxetine.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Paroxetine.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Paroxetine.Approved, Investigational
Insulin AspartParoxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirParoxetine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineParoxetine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineParoxetine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanParoxetine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproParoxetine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Paroxetine.Approved
Ioflupane I-123Paroxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Paroxetine.Approved
IproclozideIproclozide may increase the serotonergic activities of Paroxetine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Paroxetine.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Paroxetine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Paroxetine.Approved
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Paroxetine.Approved, Vet Approved
IsoniazidThe metabolism of Paroxetine can be decreased when combined with Isoniazid.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Paroxetine.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Paroxetine.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Paroxetine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Paroxetine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Paroxetine.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Paroxetine.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Paroxetine.Approved, Nutraceutical
LabetalolThe metabolism of Labetalol can be decreased when combined with Paroxetine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Paroxetine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Paroxetine.Approved, Investigational
LanreotideParoxetine may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Paroxetine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Paroxetine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Paroxetine.Approved
LenvatinibParoxetine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideParoxetine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Paroxetine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Paroxetine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paroxetine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Paroxetine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Paroxetine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Paroxetine.Approved
LevofloxacinParoxetine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Paroxetine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Paroxetine.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Paroxetine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Paroxetine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Paroxetine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Paroxetine.Approved
LinezolidLinezolid may increase the serotonergic activities of Paroxetine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Paroxetine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Paroxetine.Approved
LiraglutideParoxetine may increase the hypoglycemic activities of Liraglutide.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Paroxetine.Approved
LithiumLithium may increase the serotonergic activities of Paroxetine.Approved
LofentanilLofentanil may increase the serotonergic activities of Paroxetine.Illicit
LomustineThe metabolism of Lomustine can be decreased when combined with Paroxetine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Paroxetine.Approved
LopinavirParoxetine may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Paroxetine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Paroxetine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Paroxetine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Loxapine.Approved
Lu AA21004Paroxetine may increase the serotonergic activities of Lu AA21004.Investigational
LumefantrineParoxetine may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibParoxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Lurasidone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Paroxetine.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Paroxetine.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Paroxetine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Paroxetine.Approved
MebanazineMebanazine may increase the serotonergic activities of Paroxetine.Withdrawn
MecaserminParoxetine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Paroxetine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Paroxetine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Paroxetine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Melperone.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Paroxetine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paroxetine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.Approved, Illicit
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Paroxetine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Paroxetine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.Approved
MetforminParoxetine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Paroxetine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Paroxetine.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Paroxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Paroxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Paroxetine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Paroxetine.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Paroxetine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Paroxetine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.Approved
MethyclothiazideParoxetine may increase the hyponatremic activities of Methyclothiazide.Approved
Methylene blueParoxetine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Paroxetine.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Paroxetine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Paroxetine.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Paroxetine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Paroxetine.Approved, Illicit, Withdrawn
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Paroxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paroxetine.Approved, Investigational
MetolazoneParoxetine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Paroxetine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Paroxetine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Paroxetine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Paroxetine.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Paroxetine.Approved, Investigational
MiglitolParoxetine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Paroxetine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Paroxetine.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Paroxetine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Paroxetine.Approved, Investigational
MoclobemideMoclobemide may increase the serotonergic activities of Paroxetine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Paroxetine.Approved, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Paroxetine.Approved, Investigational
MoxifloxacinParoxetine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paroxetine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Paroxetine.Approved, Investigational
NabumetoneParoxetine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Paroxetine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Paroxetine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Paroxetine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Paroxetine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Paroxetine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Paroxetine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Paroxetine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Paroxetine.Approved
NetupitantThe metabolism of Netupitant can be decreased when combined with Paroxetine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Paroxetine.Approved
NialamideNialamide may increase the serotonergic activities of Paroxetine.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Paroxetine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Paroxetine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Paroxetine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Paroxetine.Approved
NilotinibParoxetine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Paroxetine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Paroxetine.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Paroxetine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Paroxetine.Approved
NormethadoneNormethadone may increase the serotonergic activities of Paroxetine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Paroxetine.Withdrawn
OctreotideParoxetine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OfloxacinParoxetine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Paroxetine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paroxetine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Paroxetine.Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Paroxetine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Opipramol.Investigational
OpiumOpium may increase the serotonergic activities of Paroxetine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paroxetine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Paroxetine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Paroxetine.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Paroxetine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Paroxetine.Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Paroxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paroxetine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Paroxetine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Paroxetine.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Paroxetine.Approved, Vet Approved
PaliperidoneParoxetine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Paroxetine.Approved, Investigational
PanobinostatThe serum concentration of Paroxetine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Paroxetine.Approved
ParecoxibParoxetine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Paroxetine.Approved
PasireotideParoxetine may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Paroxetine.Approved
Peginterferon alfa-2bThe serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Paroxetine.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Paroxetine.Approved
PentazocinePentazocine may increase the serotonergic activities of Paroxetine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paroxetine.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Paroxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Paroxetine.Investigational
PerflutrenParoxetine may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Paroxetine.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Paroxetine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Paroxetine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Paroxetine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Paroxetine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Paroxetine.Withdrawn
PhenelzinePhenelzine may increase the serotonergic activities of Paroxetine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Paroxetine.Approved, Withdrawn
PhenindioneParoxetine may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Paroxetine.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Paroxetine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Paroxetine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Paroxetine.Withdrawn
PhenprocoumonParoxetine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Paroxetine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Paroxetine.Approved
PioglitazoneParoxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Paroxetine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Paroxetine.Approved
PiritramidePiritramide may increase the serotonergic activities of Paroxetine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Paroxetine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Paroxetine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Paroxetine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Paroxetine.Approved
PolythiazideParoxetine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Paroxetine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Paroxetine.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Paroxetine.Approved
PramlintideParoxetine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Paroxetine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Paroxetine.Approved
PravastatinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Paroxetine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Paroxetine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Paroxetine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paroxetine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Paroxetine.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Paroxetine.Approved
PrimaquineParoxetine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Paroxetine.Approved, Vet Approved
ProcainamideParoxetine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Paroxetine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Paroxetine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Paroxetine.Approved, Vet Approved
PromazineParoxetine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Paroxetine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Paroxetine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Paroxetine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Paroxetine.Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Paroxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Paroxetine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Paroxetine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Paroxetine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Paroxetine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Paroxetine.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Paroxetine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Paroxetine.Approved, Illicit
QuetiapineParoxetine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneParoxetine may increase the hyponatremic activities of Quinethazone.Approved
QuinidineParoxetine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineParoxetine may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Paroxetine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Paroxetine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Paroxetine.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Paroxetine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Paroxetine.Approved, Withdrawn
RepaglinideParoxetine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Paroxetine.Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Paroxetine.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Paroxetine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Paroxetine.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Paroxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Paroxetine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Paroxetine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Rizatriptan.Approved
RofecoxibParoxetine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Paroxetine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Paroxetine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Paroxetine.Vet Approved
RopiniroleThe metabolism of Paroxetine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Paroxetine.Approved
RosiglitazoneParoxetine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Paroxetine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Paroxetine.Experimental
SafrazineSafrazine may increase the serotonergic activities of Paroxetine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Paroxetine.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Paroxetine.Approved, Vet Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Paroxetine.Approved, Investigational
SaxagliptinParoxetine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Paroxetine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Paroxetine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Paroxetine.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Paroxetine.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Paroxetine.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Paroxetine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Paroxetine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Paroxetine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Paroxetine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Paroxetine.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Paroxetine.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Paroxetine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Paroxetine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Paroxetine.Approved, Investigational
SotalolParoxetine may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Paroxetine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Paroxetine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Paroxetine.Experimental
StiripentolThe metabolism of Paroxetine can be decreased when combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Paroxetine.Approved, Investigational
SulfadiazineParoxetine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleParoxetine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleParoxetine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Paroxetine.Approved, Investigational
SunitinibParoxetine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Paroxetine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Paroxetine.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Paroxetine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Paroxetine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Paroxetine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Paroxetine.Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Paroxetine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Paroxetine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Paroxetine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Paroxetine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Paroxetine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Paroxetine.Investigational, Withdrawn
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Paroxetine.Approved
TelavancinParoxetine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinParoxetine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Paroxetine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Paroxetine.Approved
TerbinafineThe metabolism of Paroxetine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Paroxetine.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Paroxetine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Paroxetine.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Paroxetine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Paroxetine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Paroxetine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paroxetine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Paroxetine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paroxetine.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Paroxetine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Paroxetine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Paroxetine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Thiothixene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Paroxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tianeptine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Paroxetine.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Paroxetine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Paroxetine.Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Paroxetine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Paroxetine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Paroxetine.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Paroxetine.Approved
TolazamideParoxetine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideParoxetine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Paroxetine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Paroxetine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Paroxetine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Paroxetine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Paroxetine.Approved, Investigational
ToremifeneParoxetine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Paroxetine.Approved, Investigational
TramadolParoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Paroxetine.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Paroxetine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Paroxetine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Paroxetine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Paroxetine.Approved, Investigational, Nutraceutical
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.Approved
TrichlormethiazideParoxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paroxetine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.Approved
TropisetronTropisetron may increase the serotonergic activities of Paroxetine.Investigational
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Paroxetine.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Paroxetine.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Paroxetine.Approved
ValdecoxibParoxetine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Paroxetine.Approved, Investigational
VandetanibParoxetine may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Paroxetine.Approved
VemurafenibParoxetine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Paroxetine.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Paroxetine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Paroxetine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Paroxetine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Paroxetine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Paroxetine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Paroxetine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Paroxetine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Paroxetine.Approved
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Paroxetine.Approved
WarfarinParoxetine may increase the anticoagulant activities of Warfarin.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Paroxetine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Paroxetine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Paroxetine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Paroxetine.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Paroxetine.Approved
ZimelidineParoxetine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneParoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Paroxetine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paroxetine.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Paroxetine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paroxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Zotepine.Approved
ZuclopenthixolParoxetine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis Reference

Charles M. Zepp, Yun Gao, Donald L. Heefner, “Method of preparing optically pure precursors of paroxetine.” U.S. Patent US5258517, issued January, 1976.

US5258517
General References
  1. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [PubMed:16272179 ]
  2. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999 Aug;175:120-6. [PubMed:10627793 ]
  3. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ: Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb;16(1):3-8. [PubMed:8834412 ]
  4. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B: Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998 Aug;18(4):274-81. [PubMed:9690692 ]
  5. Waldinger MD, Zwinderman AH, Olivier B: SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001 Dec;21(6):556-60. [PubMed:11763001 ]
External Links
ATC CodesN06AB05
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (299 KB)
MSDSDownload (51.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9869
Caco-2 permeable+0.5195
P-glycoprotein substrateSubstrate0.6555
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.6771
Renal organic cation transporterInhibitor0.5222
CYP450 2C9 substrateNon-substrate0.9265
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6004
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.8298
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8649
Ames testNon AMES toxic0.6722
CarcinogenicityNon-carcinogens0.9046
BiodegradationNot ready biodegradable0.995
Rat acute toxicity2.8239 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5554
hERG inhibition (predictor II)Non-inhibitor0.5879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Apotex inc
  • Mylan pharmaceuticals inc
  • Actavis elizabeth llc
  • Alphapharm pty ltd
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Zydus pharmaceuticals usa inc
  • Noven therapeutics llc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral7.5 mg/1
TabletOral10 mg/1
TabletOral30 mg/1
TabletOral40 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral40 mg/1
TabletOral20 mg/1
SuspensionOral10 mg/5mL
Tablet, extended releaseOral12.5 mg
Tablet, extended releaseOral25 mg
Tablet, extended releaseOral37.5 mg
Tablet, film coated, extended releaseOral12.5 mg/1
Tablet, film coated, extended releaseOral25 mg/1
TabletOral10 mg
TabletOral20 mg
TabletOral30 mg
Tablet, film coated, extended releaseOral37.5 mg/1
TabletOral40 mg
Prices
Unit descriptionCostUnit
Paxil 30 40 mg tablet Bottle138.39USD bottle
Paxil 30 30 mg tablet Bottle131.0USD bottle
Paxil 30 10 mg tablet Bottle121.87USD bottle
Pexeva 40 mg tablet6.29USD tablet
Pexeva 30 mg tablet6.11USD tablet
Pexeva 20 mg tablet5.84USD tablet
Pexeva 10 mg tablet5.6USD tablet
Paxil CR 37.5 mg 24 Hour tablet4.5USD tablet
Paxil 40 mg tablet4.44USD tablet
Paxil CR 25 mg 24 Hour tablet4.37USD tablet
Paxil cr 37.5 mg tablet4.32USD tablet
Paxil 30 mg tablet4.2USD tablet
Paxil cr 25 mg tablet4.2USD tablet
Paxil CR 12.5 mg 24 Hour tablet4.18USD tablet
Paxil 20 mg tablet4.16USD tablet
PARoxetine HCl 37.5 mg 24 Hour tablet4.04USD tablet
Paxil cr 12.5 mg tablet4.02USD tablet
PARoxetine HCl 25 mg 24 Hour tablet3.93USD tablet
Paxil 10 mg tablet3.91USD tablet
PARoxetine HCl 12.5 mg 24 Hour tablet3.76USD tablet
Paroxetine hcl 40 mg tablet2.93USD tablet
Paroxetine hcl 30 mg tablet2.78USD tablet
Paroxetine hcl 20 mg tablet2.7USD tablet
Paroxetine hcl 10 mg tablet2.58USD tablet
Paxil 30 mg Tablet2.16USD tablet
Pms-Paroxetine 40 mg Tablet2.1USD tablet
Paxil 20 mg Tablet2.03USD tablet
Apo-Paroxetine 30 mg Tablet1.12USD tablet
Co Paroxetine 30 mg Tablet1.12USD tablet
Mylan-Paroxetine 30 mg Tablet1.12USD tablet
Novo-Paroxetine 30 mg Tablet1.12USD tablet
Phl-Paroxetine 30 mg Tablet1.12USD tablet
Pms-Paroxetine 30 mg Tablet1.12USD tablet
Ratio-Paroxetine 30 mg Tablet1.12USD tablet
Sandoz Paroxetine 30 mg Tablet1.12USD tablet
Apo-Paroxetine 20 mg Tablet1.05USD tablet
Co Paroxetine 20 mg Tablet1.05USD tablet
Mylan-Paroxetine 20 mg Tablet1.05USD tablet
Novo-Paroxetine 20 mg Tablet1.05USD tablet
Phl-Paroxetine 20 mg Tablet1.05USD tablet
Pms-Paroxetine 20 mg Tablet1.05USD tablet
Ratio-Paroxetine 20 mg Tablet1.05USD tablet
Sandoz Paroxetine 20 mg Tablet1.05USD tablet
Paxil 10 mg/5ml Suspension0.85USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2168829 No1997-12-162016-02-05Canada
CA2445678 No2009-11-242016-07-19Canada
US5789449 No1992-07-062009-07-06Us
US5811436 Yes1996-03-222016-03-22Us
US5872132 Yes1995-11-192015-11-19Us
US5874447 No1997-06-102017-06-10Us
US5900423 Yes1995-11-192015-11-19Us
US6063927 Yes1999-10-232019-10-23Us
US6080759 Yes1995-11-192015-11-19Us
US6121291 Yes1997-09-172017-09-17Us
US6133289 Yes1995-11-192015-11-19Us
US6172233 Yes1998-07-152018-07-15Us
US6548084 Yes1997-01-192017-01-19Us
US6703408 No2002-10-212022-10-21Us
US7229640 Yes1997-01-192017-01-19Us
US7598271 No2003-02-122023-02-12Us
US8658663 No2009-04-062029-04-06Us
US8946251 No2006-08-042026-08-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point147-150 °C (mesylate salt) FDA label
water solubility>1 g/mL (mesylate salt) Not Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00853 mg/mLALOGPS
logP3.1ALOGPS
logP3.15ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area39.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.02 m3·mol-1ChemAxon
Polarizability34.48 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-8900000000-0a273deac3c7836cdc76View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Benzodioxole
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Oxacycle
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8. [PubMed:10869387 ]
  2. Preuss UW, Soyka M, Bahlmann M, Wenzel K, Behrens S, de Jonge S, Kruger M, Bondy B: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Psychiatry Res. 2000 Sep 25;96(1):51-61. [PubMed:10980326 ]
  3. Haughey HM, Fleckenstein AE, Metzger RR, Hanson GR: The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem. 2000 Oct;75(4):1608-17. [PubMed:10987842 ]
  4. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90. [PubMed:11027924 ]
  5. Wihlback AC, Sundstrom-Poromaa I, Allard P, Mjorndal T, Spigset O, Backstrom T: Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol. 2001 Sep;98(3):450-7. [PubMed:11530128 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Rubin RT: Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry. 2000 Nov 1;48(9):954-6. [PubMed:11203183 ]
  2. Gilmor ML, Owens MJ, Nemeroff CB: Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002 Oct;159(10):1702-10. [PubMed:12359676 ]
  3. Nemeroff CB, Owens MJ: Neuropharmacology of paroxetine. Psychopharmacol Bull. 2003 Spring;37 Suppl 1:8-18. [PubMed:14566196 ]
  4. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Bixo M, Allard P, Backstrom T, Mjorndal T, Nyberg S, Spigset O, Sundstrom-Poromaa I: Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology. 2001 Aug;26(6):551-64. [PubMed:11403977 ]
  2. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH: The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001 Jan;158(1):78-85. [PubMed:11136637 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  3. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther. 1997 Sep;62(3):334-47. [PubMed:9333110 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 03:59